GlassScriptPhysician profile
Vikram Aggarwal
NPI 1316235583
$116,630.96
in general payments reported to CMS, 2019-2025
13 companies · $78K in 2025
The $78K reported for 2025 was more than what 99% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $194 · 2021: $5,150 · 2022: $4,641 · 2023: $14K · 2024: $15K · 2025: $78K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $37K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $24K · Honoraria: $21K · Travel and Lodging: $13K · Education: $7,623 · Food and Beverage: $3,489.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $37,463.76 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $24,184.50 |
| Honoraria | $21,137.50 |
| Travel and Lodging | $12,748.80 |
| Education | $7,622.86 |
| Food and Beverage | $3,488.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vantive US Healthcare LLC | $33,488.61 | 2025 | Renal - Chronic, Renal - Pd, Renal - Amia |
| Calliditas Therapeutics US INC. | $30,926.83 | 2023-2025 | Tarpeyo |
| Akebia Therapeutics INC | $26,951.81 | 2025 | Vafseo |
| Outset Medical INC | $20,034.16 | 2021-2024 | |
| Baxter Healthcare | $4,614.40 | 2023-2024 | Renal - Acute, Renal - Amia |
| Nxstage Medical, INC. | $301.33 | 2019-2025 | Nxstage System One, Liberty Select Cycler |
| Alnylam Pharmaceuticals INC. | $116.68 | 2019 | |
| Alexion Pharmaceuticals, INC. | $79.99 | 2024 | Soliris |
| Next Science LLC | $37.75 | 2025 | Xperience, Blastx |
| Abbott Laboratories | $24.06 | 2023 | Confirm Rx |
| Ardelyx, INC. | $19.97 | 2025 | Ibsrela |
| Amgen INC. | $18.48 | 2023 | Tavneos |
| Travere Therapeutics, INC. | $16.89 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vikram Aggarwal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.